Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Willingham

Showing results (41-50 of 100) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersRaffit Hassan, Susie Bullock, Ahalya Premkumar, et al.
Cancer Immunity|November 1, 2006
Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR miceAmy M Hicks, Mark C Willingham, Wei Du, et al.
Molecular Cancer Therapeutics|August 27, 2003
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapyTie Fu Liu, Stephen B Tatter, Mark C Willingham, et al.
Pediatric Nephrology (Berlin, Germany)|April 22, 2005
Clinico-pathologic findings in medullary cystic kidney disease type 2Anthony J Bleyer, Thomas C Hart, Mark C Willingham, et al.
Journal of Lipid Research|April 3, 2004
Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusionsShaila Bhat, Manal Zabalawi, Mark C Willingham, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 24, 2013
Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor αLaura Fozzatti, Dong Wook Kim, Jeong Won Park, et al.
Cancer Research|April 19, 2003
A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cellsTie Fu Liu, Kimberley A Cohen, Jason G Ramage, et al.
Journal of Neuro-Oncology|December 3, 2003
Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell cultureTie Fu Liu, Kimberly A Cohen, Mark C Willingham, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 21, 2004
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markersJacqueline K Trupiano, Kim R Geisinger, Mark C Willingham, et al.
Immunity|February 16, 2008
Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contractionAshley E Weant, Ryan D Michalek, Islam U Khan, et al.
Pageof 10

Showing results (41-50 of 100) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersRaffit Hassan, Susie Bullock, Ahalya Premkumar, et al.
Cancer Immunity|November 1, 2006
Effector mechanisms of the anti-cancer immune responses of macrophages in SR/CR miceAmy M Hicks, Mark C Willingham, Wei Du, et al.
Molecular Cancer Therapeutics|August 27, 2003
Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapyTie Fu Liu, Stephen B Tatter, Mark C Willingham, et al.
Pediatric Nephrology (Berlin, Germany)|April 22, 2005
Clinico-pathologic findings in medullary cystic kidney disease type 2Anthony J Bleyer, Thomas C Hart, Mark C Willingham, et al.
Journal of Lipid Research|April 3, 2004
Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusionsShaila Bhat, Manal Zabalawi, Mark C Willingham, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 24, 2013
Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor αLaura Fozzatti, Dong Wook Kim, Jeong Won Park, et al.
Cancer Research|April 19, 2003
A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cellsTie Fu Liu, Kimberley A Cohen, Jason G Ramage, et al.
Journal of Neuro-Oncology|December 3, 2003
Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell cultureTie Fu Liu, Kimberly A Cohen, Mark C Willingham, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 21, 2004
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markersJacqueline K Trupiano, Kim R Geisinger, Mark C Willingham, et al.
Immunity|February 16, 2008
Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contractionAshley E Weant, Ryan D Michalek, Islam U Khan, et al.
Pageof 10